Puma Biotechnology Patent-Cliff Exposure & CMS Drug Spending Portfolio

Puma Biotechnology (Los Angeles, CA): 1 reconciled FDA prescription therapies, $60.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterLos Angeles, CA
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$60.6M
2024 Medicare Part D Spend$38.4M
2024 Medicaid Spend$22.2M
California HCAI SB 17 Filings8 WAC filings (max 24.0% 2-yr change)